Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a five-year follow-up of participants who received a single intravitreal i ...
Nanoscope Therapeutics President and Chief Scientific Officer Dr. Samarendra Mohanty to Be Featured Speaker at 2025 ISPE Annual Meeting and Expo
DALLAS, Oct. 27, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vi ...
Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa
REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profileThe data f ...
Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting
DALLAS, Oct. 13, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vis ...
Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations
European Medicines Agency grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant ...
Nanoscope Announces Groundbreaking 3-Year REMAIN Trial Data for Patients with Retinitis Pigmentosa at 2025 Euretina Congress and Retina Society Annual Scientific Meeting
Talks highlight efficacy, durability, and safety of Nanoscope's MCO (multi-characteristic opsin) optogenetic therapy platform Data forms the foundation for recent rolling Biologics License Application ...
Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
The STARLIGHT study is the first and only clinical trial to demonstrate vision improvement in patients with Stargardt disease.MCO-010 demonstrated mean visual acuity improvement of 12 ETDRS letters ov ...
Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting
126-week results from RESTORE follow-up study (REMAIN) to highlight the extended efficacy and safety of Nanoscope's MCO-010 optogenetic therapy for Retinitis PigmentosaDALLAS, July 28, 2025 /PRNewswir ...
Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology
New research paper highlights the unique structure and function of Nanoscope's synthetic opsin, supporting its potential in vision restoration DALLAS, July 22, 2025 -- Nanoscope Therapeutics Inc., a b ...
Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa
First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026 MCO-010 BLA for retinitis pigmentosa is eligible for priority review based on fast-track de ...
Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting
Presentations will highlight durability, efficacy and safety of Nanoscope's optogenetic therapy platforms DALLAS, May 12, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotech company c ...
Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee
DALLAS, June 26, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from ...
Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration
Batabyal receives 2025 Carl Camras Translational Research Award from ARVO Foundation DALLAS, May 1, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restorin ...
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2025 Annual Meetings
Presentations to highlight efficacy, durability, and safety of Nanoscope's optogenetic therapy platforms DALLAS, April 25, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to ...
Pharmaceutical Industry Veteran, Ashish Patel, PhD, Joins Nanoscope as Senior Vice President of Sales and Marketing
DALLAS, March 27, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today ...
Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
DALLAS, March 24, 2025 -- Researchers with Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing ...
Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality & Compliance
DALLAS, March 20, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene ther ...
Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access
DALLAS, March 5, 2025 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), t ...
Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase
DALLAS, March 13, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerati ...